New COVID vaccines may offer broad protection from coronaviruses

New COVID vaccines may offer broad protection from coronaviruses
UVA’s Dr. Steven Zeichner, left, and Virginia Tech’s Dr. Xiang-Jin Meng’s discovery might one day open the door to a universal vaccine for coronaviruses. Credit: Zeichner photo by Sanjay Suchak, University Communications; Meng photo courtesy of Virginia Tech

A COVID-19 vaccine that could provide protection against both existing and future strains of the COVID-19 virus, and other coronavirusesat a cost of about $1 a dose has shown promising results in early animal testing.

Vaccines created by UVA Health's Dr. Steven L. Zeichner and Virginia Tech's Dr. Xiang-Jin Meng prevented pigs from being becoming ill with a pig model coronavirus, porcine epidemic diarrhea virus. The was developed using an innovative approach that Zeichner said might one day open the door to a for coronaviruses, including coronaviruses that previously threatened pandemics or perhaps even coronaviruses that cause some cases of the common cold.

Their coronavirus vaccine offers several advantages that could overcome major obstacles to global vaccination efforts. It would be easy to store and transport, even in remote areas of the world, and could be produced in mass quantities using existing vaccine-manufacturing factories.

The UVA and Virginia Tech scientists created the vaccine using a new platform Zeichner invented to rapidly develop new vaccines. So the testing success bodes well for both the COVID-19 vaccine and Zeichner's vaccine-development approach.

"Our new platform offers a new route to rapidly produce vaccines at very low cost that can be manufactured in existing facilities around the world, which should be particularly helpful for pandemic response," Zeichner said.

A New Vaccine-Development Approach

Zeichner's new vaccine-production platform involves synthesizing DNA that directs the production of a piece of the virus that can instruct the how to mount a protective immune response against the virus.

That DNA is inserted into another small circle of DNA called a plasmid that can reproduce within bacteria. The plasmid is then introduced into bacteria, instructing the bacteria to place pieces of proteins on their surfaces. The technique uses the common bacteria E. coli.

One major innovation is that the E. coli have had a large number of its genes deleted. Removing many of the bacteria's genes, including genes that make up part of its exterior surface or outer membrane, appears to substantially increase the ability of the immune system to recognize and respond to the vaccine antigen placed on the surface of the bacteria.

To produce the vaccine, the bacteria expressing the vaccine antigen are simply grown in a fermenter, much like the fermenters used in common microbial industrial processes like brewing, and then killed with a low concentration of formalin.

"Killed whole-cell vaccines are currently in widespread use to protect against deadly diseases like cholera and pertussis. Factories in many low- to around the world are making hundreds of millions of doses of those vaccines per year now, for a $1 per dose or less," Zeichner said. "It may be possible to adapt those factories to make this new vaccine. Since the technology is very similar, the cost should be similar, too."

The entire process, from identifying a potential vaccine target to producing the gene-deleted bacteria that have the vaccine antigens on their surfaces, can take place very quickly, in only two to three weeks, making the platform ideal for responding to a pandemic.

Targeting COVID-19

Zeichner and Meng's vaccine takes an unusual approach in that it targets a part of the spike protein of the virus, the viral fusion peptide, that is essentially universal among coronaviruses. The fusion peptide has not been observed to differ at all in the many genetic sequences of SARS-CoV-2, the virus that causes COVID-19, that have been obtained from thousands of patients around the world during the pandemic.

Meng and Zeichner made two vaccines, one designed to protect against COVID-19, and another designed to protect against porcine epidemic diarrhea virus. Both are coronaviruses, but they are distant relatives. Porcine epidemic diarrhea and SARS-CoV-2, like all coronaviruses, share several of the amino acids that constitute the fusion peptide. PEDV infects pigs, causing diarrhea, vomiting and high fever, and has been a large burden on pig farmers around the world. When PEDV first appeared in pig herds in the U.S., it killed almost 10% of U.S. pigs—a pig pandemic.

Explore further

A single vaccine to beat all coronaviruses sounds impossible—but scientists are already working on one

More information: Denicar Lina Nascimento Fabris Maeda et al. Killed whole genome-reduced bacteria surface-expressed coronavirus fusion peptide vaccines protect against disease in a porcine model, biorxiv (2021). DOI: 10.1101/2021.03.15.435497
Citation: New COVID vaccines may offer broad protection from coronaviruses (2021, March 25) retrieved 3 July 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors